Evolution of antitumor treatment for primary glial CNS tumors
Slugina E.A., Novik A.V., Nekhaeva T.L., Efremova N.A., Kurnosov I.A., Danilova A.B., Baldueva I.A.
Gliomas are a group of central nervous system (CNS) tumors originating from glial cells. Despite significant efforts in the field of oncology, gliomas, especially high-grade gliomas, remain one of the most complex and aggressive forms of malignancy. Low-grade diffuse gliomas have a relatively favorable prognosis, while high-grade gliomas, especially glioblastomas, are characterized by an extremely unfavorable course. The overall survival (OS) of patients with glioblastoma ranges from 14 to 20 months, and the 5-year survival rate is only 6%. In patients with newly diagnosed glioblastoma, the 6-month progression-free survival (PFS) is approximately 54%, while in relapsed patients, the 6-month PFS is 30–40%, and the 6-month OS is 57%. For newly diagnosed diffuse glial tumors WHO G3–4, the 1-year PFS is approximately 80%, and the median OS is approximately 25 months. These indicators emphasize the need to search for new treatment approaches. This article presents the main current strategies and approaches to the treatment of diffuse glial CNS tumors. A meta-analysis of the efficacy of the combination of bevacizumab and irinotecan was conducted.
For citations: Slugina E.A., Novik A.V., Nekhaeva T.L., Efremova N.A., Kurnosov I.A., Danilova A.B., Baldueva I.A. Evolution of antitumor treatment for primary glial CNS tumors. Pharmateca. 2025;32(9):108-118. (In Russ.). DOI: https://dx.doi.org/10.18565/pharmateca.2025.9.108-118
Authors’ contribution: Study concept and design – E.A. Slugina, A.V. Novik. Data collection and processing – T.L. Nekhaeva, N.A. Efremova, I.A. Kurnosov, A.B. Danilova, I.A. Baldueva. Statistical data processing – A.V. Novik, E.A. Slugina. Writing – E.A. Slugina, A.V. Novik. Editing – all authors. General supervision and approval of the final version – E.A. Slugina, A.V. Novik.
Conflicts of interest: The authors confirm that they have no conflicts of interest to declare.
Funding: The study was conducted without any sponsorship.
Keywords
glioma
glioblastoma
astrocytoma
oligodendroglioma
targeted therapy
immunotherapy
About the Authors
E.A. Slugina, Oncologist, N.N. Petrov National Medical Research Center of Oncology, St. Petersburg, Russia; emureyko@mail.ru, ORCID: https://orcid.org/0000-0003-1626-082X, eLibrary SPIN: 2023-1598V.A. Novik, Dr. Sci. (Med.), Oncologist, Oncoimmunologist, Oncoimmunology Research Department, N.N. Petrov National Medical Research Center of Oncology; Saint Petersburg State Pediatric Medical University, St. Petersburg, Russia; anovik@list.ru, ORCID: https://orcid.org/0000-0002-2430-4709, eLibrary SPIN: 4549-7885 (corresponding author)
T.L. Nekhaeva, Cand. Sci. (Med.), Head of the Oncoimmunology Research Department, N.N. Petrov National Medical Research Center of Oncology, St. Petersburg, Russia; nehaevat151274@mail.ru, ORCID: https://orcid.org/0000-0002-7826-4861, SPIN (RINTS) 5366-8969, Researcher ID (WOS) L-7268-2018, Author ID: 759111
N.A. Efremova, Cand. Sci. (Med.), Oncologist, Oncoimmunologist, Oncoimmunology Research Department, N.N. Petrov National Medical Research Center of Oncology; St. Petersburg, Russia; nataliaavdonkina@gmail.com, SPIN code: 7352-9350, AuthorID: 821553
I.A. Kurnosov, Cand. Sci. (Med.), Head of the Department of Neuro-Oncology, Junior Researcher, Scientific Department of Neuro-Oncology and Endoscopy, N.N. Petrov National Medical Research Center of Oncology; St. Petersburg, Russia; ivkurnosov@gmail.com, ORCID: https://orcid.org/0000-0003-2857-8368, SPIN: 9131-7381
A.B. Danilova, Dr. Sci. (Med.), Oncoimmunologist, Senior Reseacher, Oncoimmunology Research Department, N.N. Petrov National Medical Research Center of Oncology, St. Petersburg, Russia, ORCID: https://orcid.org/0000-0003-4796-0386, SPIN: 9387-8328, Researcher ID (WOS): H-7828-2014, Scopus Author ID: 7005563064
I.A. Baldueva, Dr. Sci. (Med.), Chief Researcher, Oncoimmunology Research Department, N.N. Petrov National Medical Research Center of Oncology, St. Petersburg, Russia; biahome@mail.ru, ORCID: https://orcid.org/0000-0002-7472-4613, SPIN: 7512-8789
Similar Articles
